Jay S Stout sold $51k of IMVT
Chief Technology Officer at Immunovant, Inc.. 2,805 shares at an average of $18.15, traded Jul 23, 2025, filed Jul 25, 2025.
Score components
- +15RoleOfficer
- +7Trade size$51k at market
- 0Share of holdings soldSold 1.4% of holdings
- +8Cluster2 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001764013-25-000115, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jul 23, 2025 | SOpen-market sale Common Stock | -2,805 | $18.15 | $51k | 204,919 | Jul 25, 2025 |
Related signals
Other insiders at Immunovant, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $72k 2,241 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Jay S Stout Chief Technology Officer | $122k 3,809 shares | -2% | |
| 36Weak | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $43k 1,327 shares | -1% | |
| 35Weak | Immunovant, Inc. | Eric Venker Chief Executive Officer | $120k 3,506 shares | -1% | |
| 40Moderate | Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $103k 2,846 shares | -2% | |
| 29Weak | IMVTsell Immunovant, Inc. | Christopher Van Tuyl Chief Legal Officer | $291k 10,813 shares | -7% | |
| 43Moderate | IMVTbuy Immunovant, Inc. | Roivant Sciences Ltd. director, owner | $350M 16,666,666 shares | +17% | |
| 33Weak | Immunovant, Inc. | Andrew J. Fromkin director | $517k 22,249 shares | -21% | |
| 30Weak | Immunovant, Inc. | Douglas J. Hughes director | $349k 15,000 shares | -11% | |
| 49Moderate | Immunovant, Inc. | Melanie Gloria Chief Operating Officer | $298k 12,626 shares | -7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.